RxDoctor Payments DataLook up a doctor →

Kamran Ghalili, MD

Cardiovascular Disease · Salem, ORNPI 1417977166

Payments from drug & device makers

$10,569in general payments, 2019–2025

Across 549 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Boston Scientific$1K
  • Pfizer$1K
  • E.r. Squibb & Sons, L.L.C.$834
  • Boehringer Ingelheim$547
  • Merck$540
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$10,32098%
  • Education$2502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,569 in reported general payments places this provider in the 80th percentile of 198 cardiovascular disease providers in Oregon.

See all cardiovascular disease providers in Oregon

Medicare billing

Part B allowed, 2024
$521,013
Medicare patients
931
Services billed
3,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban498$567,661
XareltoRivaroxaban148$190,069
Repatha SureclickEvolocumab74$44,509
EntrestoSacubitril/Valsartan21$24,581
Metoprolol Succinate973$12,752
Flecainide Acetate150$6,259
Atorvastatin Calcium409$5,279
Diltiazem 24hr ErDiltiazem Hcl101$3,528
Lisinopril441$3,328
Amlodipine Besylate478$3,075
Losartan Potassium315$2,948
ClopidogrelClopidogrel Bisulfate270$2,537
Diltiazem 24hr Er (Cd)Diltiazem Hcl67$2,500
Isosorbide Mononitrate ErIsosorbide Mononitrate243$2,478
Amiodarone Hcl92$2,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,105$567,661498 claims
Johnson & JohnsonXarelto$328$190,069148 claims
NovartisEntresto$1,724$24,58121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 198 cardiovascular disease providers in Oregon.

Other cardiovascular disease in Salem

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →